Fezakinumab

Fezakinumab
Monoclonal antibody
TypeWhole antibody
TargetIL-22
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6408H9873N1706O2016S44
Molar mass144479.04 g·mol−1
 NY (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
  2. ^ "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.